

# DÃ©la Golshayan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/302076/publications.pdf>

Version: 2024-02-01

84  
papers

2,967  
citations

201385

27  
h-index

174990

52  
g-index

88  
all docs

88  
docs citations

88  
times ranked

4842  
citing authors

#	ARTICLE	IF	CITATIONS
1	Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. <i>Blood</i> , 2007, 109, 2058-2065.	0.6	429
2	In vitro "expanded donor alloantigen" specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. <i>Blood</i> , 2007, 109, 827-835.	0.6	298
3	A Novel Pathway of Alloantigen Presentation by Dendritic Cells. <i>Journal of Immunology</i> , 2004, 173, 4828-4837.	0.4	293
4	Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity. <i>EMBO Journal</i> , 2014, 33, 2765-2781.	3.5	129
5	Treg-Therapy Allows Mixed Chimerism and Transplantation Tolerance Without Cytoablative Conditioning. <i>American Journal of Transplantation</i> , 2010, 10, 751-762.	2.6	127
6	First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. <i>American Journal of Transplantation</i> , 2020, 20, 2876-2882.	2.6	102
7	Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. <i>Journal of Clinical Investigation</i> , 2011, 121, 2794-2807.	3.9	86
8	Update on Dendritic Cell-Induced Immunological and Clinical Tolerance. <i>Frontiers in Immunology</i> , 2017, 8, 1514.	2.2	83
9	Immunosuppressive Effects of Streptozotocin-Induced Diabetes Result in Absolute Lymphopenia and a Relative Increase of T Regulatory Cells. <i>Diabetes</i> , 2011, 60, 2331-2340.	0.3	73
10	A Novel Pathway of Antigen Presentation by Dendritic and Endothelial Cells: Implications for Allorecognition and Infectious Diseases. <i>Transplantation</i> , 2006, 82, S15-S18.	0.5	71
11	Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. <i>European Heart Journal</i> , 2010, 31, 67-76.	1.0	71
12	Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H3415-H3423.	1.5	56
13	BK Polyomavirus-Specific 9mer CD8 T Cell Responses Correlate With Clearance of BK Viremia in Kidney Transplant Recipients: First Report From the Swiss Transplant Cohort Study. <i>American Journal of Transplantation</i> , 2017, 17, 2591-2600.	2.6	52
14	From current immunosuppressive strategies to clinical tolerance of allografts. <i>Transplant International</i> , 2007, 20, 12-24.	0.8	51
15	Oxidized LDL Modulates Apoptosis of Regulatory T Cells in Patients with ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1368-1384.	3.0	50
16	Achieving Permanent Survival of Islet Xenografts by Independent Manipulation of Direct and Indirect T-Cell Responses. <i>Diabetes</i> , 2005, 54, 1048-1055.	0.3	47
17	Tolerance-Inducing Immunosuppressive Strategies in Clinical Transplantation. <i>Drugs</i> , 2008, 68, 2113-2130.	4.9	46
18	Anti-CD154 mAb and Rapamycin Induce T Regulatory Cell Mediated Tolerance in Rat-to-Mouse Islet Transplantation. <i>PLoS ONE</i> , 2010, 5, e10352.	1.1	42

#	ARTICLE	IF	CITATIONS
19	Fibroblast activation protein-1 in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?. Expert Opinion on Therapeutic Targets, 2017, 21, 977-991.	1.5	42
20	Notch Antagonists: Potential Modulators of Cancer and Inflammatory Diseases. Journal of Medicinal Chemistry, 2016, 59, 7719-7737.	2.9	38
21	Lipoxin A4 Prevents the Progression of De Novo and Established Endometriosis in a Mouse Model by Attenuating Prostaglandin E2 Production and Estrogen Signaling. PLoS ONE, 2014, 9, e89742.	1.1	38
22	Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation. Kidney International, 2016, 89, 927-938.	2.6	37
23	Incidence and prognostic value of electrocardiographic abnormalities after heart transplantation. Clinical Cardiology, 1998, 21, 680-684.	0.7	36
24	CD4+CD25+Foxp3+ regulatory T cells: from basic research to potential therapeutic use. Swiss Medical Weekly, 2007, 137, 625-34.	0.8	36
25	Clinically-relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation. Human Immunology, 2016, 77, 483-489.	1.2	35
26	T regulatory cells in xenotransplantation. Xenotransplantation, 2009, 16, 121-128.	1.6	34
27	Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation. Transplant Immunology, 2008, 20, 21-28.	0.6	32
28	Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort. Kidney International, 2006, 69, 1424-1430.	2.6	29
29	Therapeutic Efficacy of Polyclonal Tregs Does Not Require Rapamycin in a Low-Dose Irradiation Bone Marrow Transplantation Model. Transplantation, 2011, 92, 280-288.	0.5	27
30	Laparoscopic right nephrectomy for live kidney donation: functional results. Transplant International, 2003, 16, 419-424.	0.8	25
31	Patient referral is influenced by dialysis centre structure in the Diamant Alpin Dialysis cohort study. Nephrology Dialysis Transplantation, 2004, 19, 2341-2346.	0.4	24
32	Transplantation tolerance: Clinical potential of regulatory T cells. Self/nonself, 2011, 2, 26-34.	2.0	20
33	In vitro expanded alloantigen-specific CD4+CD25+ regulatory T cell treatment for the induction of donor-specific transplantation tolerance. International Immunopharmacology, 2006, 6, 1879-1882.	1.7	18
34	Potential of T-regulatory cells to protect xenografts. Current Opinion in Organ Transplantation, 2012, 17, 155-161.	0.8	18
35	Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction. Journal of Medicinal Chemistry, 2018, 61, 9811-9840.	2.9	18
36	Transplantation tolerance induced by regulatory T cells: In vivo mechanisms and sites of action. International Immunopharmacology, 2009, 9, 683-688.	1.7	16

#	ARTICLE	IF	CITATIONS
37	Differential Role of Na <sup>+</sup> ve and Memory CD4+ T-Cell Subsets in Primary Alloresponses. American Journal of Transplantation, 2010, 10, 1749-1759.	2.6	16
38	The Rational Use of Complement Inhibitors in Kidney Diseases. Kidney International Reports, 2022, 7, 1165-1178.	0.4	16
39	Regulation of Rat and Human T-Cell Immune Response by Pharmacologically Modified Dendritic Cells. Transplantation, 2009, 87, 1617-1628.	0.5	15
40	Impact of different urinary tract infection phenotypes within the first year post-transplant on renal allograft outcomes. American Journal of Transplantation, 2022, 22, 1823-1833.	2.6	15
41	MR imaging as a specific diagnostic tool for bilateral microcysts in chronic lithium nephropathy. Kidney International, 2012, 81, 601.	2.6	14
42	Targeted $\hat{3}$ -Secretase Inhibition To Control the Notch Pathway in Renal Diseases. Journal of Medicinal Chemistry, 2015, 58, 8097-8109.	2.9	14
43	Differential Effects of the Mitochondria-Active Tetrapeptide SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH <sub>2</sub> ) and Its Peptidase-Targeted Prodrugs in Experimental Acute Kidney Injury. Frontiers in Pharmacology, 2019, 10, 1209.	1.6	14
44	Potential and limitations of regulatory T-cell therapy in solid organ transplantation. Expert Review of Clinical Immunology, 2014, 10, 1197-1212.	1.3	12
45	Mortality Prediction after the First Year of Kidney Transplantation: An Observational Study on Two European Cohorts. PLoS ONE, 2016, 11, e0155278.	1.1	12
46	Mycophenolic acid formulations in adult renal transplantation &ndash; update on efficacy and tolerability. Therapeutics and Clinical Risk Management, 2009, 5, 341.	0.9	11
47	CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation. Pharmacogenomics Journal, 2017, 17, 69-75.	0.9	11
48	Phenytoin-associated severe hypocalcemia with seizures in a patient with a <i>TSC2-PKD1 </i>contiguous gene syndrome. Renal Failure, 2013, 35, 866-868.	0.8	10
49	Regulation of Fibroblast Activation Protein- $\hat{1}$ Expression: Focus on Intracellular Protein Interactions. Journal of Medicinal Chemistry, 2021, 64, 14028-14045.	2.9	10
50	Enhanced and aberrant <scp>T</scp> cell trafficking following total body irradiation: a gateway to graft-versus-host disease?. British Journal of Haematology, 2013, 162, 808-818.	1.2	9
51	IL-2-Mediated In Vivo Expansion of Regulatory T Cells Combined with CD154 $\hat{1}$ CD40 Co-Stimulation Blockade but Not CTLA-4 Ig Prolongs Allograft Survival in Naive and Sensitized Mice. Frontiers in Immunology, 2017, 8, 421.	2.2	9
52	Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation. Transplant International, 2018, 31, 451-455.	0.8	9
53	Pre-transplant donor-specific HLA antibodies and risk for poor first-year renal transplant outcomes: results from the Swiss Transplant Cohort Study. Transplant International, 2021, 34, 2755-2768.	0.8	9
54	The Diamant Alpin Dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients. Journal of Nephrology, 2004, 17, 66-75.	0.9	9

#	ARTICLE	IF	CITATIONS
55	Commentary: Priming of alloreactive T cells - where does it happen?. <i>European Journal of Immunology</i> , 2004, 34, 3301-3304.	1.6	8
56	Management of allergy transfer upon solid organ transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 834-843.	2.6	8
57	Real-life food-safety behavior and incidence of foodborne infections in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2020, 20, 1424-1430.	2.6	8
58	Laparoscopic right nephrectomy for live kidney donation: functional results. <i>Transplant International</i> , 2003, 16, 419-424.	0.8	8
59	Burden of end-stage renal disease and evolving challenges in kidney transplantation. <i>Transplant International</i> , 2019, 32, 889-891.	0.8	7
60	Dialysis after graft loss: a Swiss experience. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2182-2190.	0.4	7
61	Infection Risk in the First Year After ABO-incompatible Kidney Transplantation: A Nationwide Prospective Cohort Study. <i>Transplantation</i> , 2022, 106, 1875-1883.	0.5	7
62	Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study. <i>BMC Nephrology</i> , 2022, 23, 178.	0.8	7
63	Drug-minimization or tolerance-promoting strategies in human kidney transplantation: is Campath-1H the way to follow?. <i>Transplant International</i> , 2006, 19, 881-884.	0.8	6
64	Potassium restores vasorelaxation of resistance arterioles in non-hypertensive DOCA/salt fed mice. <i>Microvascular Research</i> , 2012, 84, 340-344.	1.1	6
65	Exploring frailty and mild cognitive impairment in kidney transplantation to predict biomedical, psychosocial and health cost outcomes (GERAS): protocol of a nationwide prospective cohort study. <i>Journal of Advanced Nursing</i> , 2017, 73, 716-734.	1.5	6
66	Targeted $\beta$ -secretase inhibition of Notch signaling activation in acute renal injury. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, F736-F746.	1.3	6
67	Upfront use of eculizumab to treat early acute antibody-mediated rejection after kidney allotransplantation and relevance for xenotransplantation. <i>Xenotransplantation</i> , 2020, 27, e12630.	1.6	6
68	Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study. <i>Swiss Medical Weekly</i> , 2020, 150, w20354.	0.8	6
69	Additive effects of rapamycin and aspirin on dendritic cell allostimulatory capacity. <i>Immunopharmacology and Immunotoxicology</i> , 2015, 37, 434-441.	1.1	5
70	Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 238-246.	2.6	5
71	Infectious complications and graft outcome following treatment of acute antibody-mediated rejection after kidney transplantation: A nationwide cohort study. <i>PLoS ONE</i> , 2021, 16, e0250829.	1.1	4
72	Therapeutic Potential of Targeting Malt1-Dependent TCR Downstream Signaling to Promote the Survival of MHC-Mismatched Allografts. <i>Frontiers in Immunology</i> , 2020, 11, 576651.	2.2	2

#	ARTICLE	IF	CITATIONS
73	Mutually exclusive lymphangiogenesis or perineural infiltration in human skin squamous-cell carcinoma. <i>Oncotarget</i> , 2021, 12, 638-648.	0.8	2
74	Optimal and continuous anaemia control in a cohort of dialysis patients in Switzerland. <i>BMC Nephrology</i> , 2008, 9, 16.	0.8	1
75	All regulators great and small: when Treg need small RNAs to fulfill their commitment. <i>Transplant International</i> , 2015, 28, 1140-1142.	0.8	1
76	Oral valganciclovir for CMV gastritis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, e50-e51.	0.7	1
77	SP695 DIALYSIS AFTER GRAFT LOSS: THE SWISS EXPERIENCE. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i580-i581.	0.4	1
78	Acute Antibody-Mediated Rejection and its Treatment in Kidney Transplantation. <i>Transplantation</i> , 2018, 102, S93.	0.5	1
79	Pre-transplant Social Adaptability Index and clinical outcomes in renal transplantation: The Swiss Transplant Cohort study. <i>Clinical Transplantation</i> , 2021, 35, e14218.	0.8	1
80	Impact of Hyponatremia after Renal Transplantation on Decline of Renal Function, Graft Loss and Patient Survival: A Prospective Cohort Study. <i>Nutrients</i> , 2021, 13, 2995.	1.7	1
81	SARS-CoV-2 / COVID-19 in patients on the Swiss national transplant waiting list. <i>Swiss Medical Weekly</i> , 2020, 150, w20451.	0.8	1
82	Acute renal dysfunction after simultaneous pancreas-kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 2610-2613.	2.6	0
83	Use of induction therapy in pediatric heart transplant recipients in Switzerland – Analysis of the Swiss national database. <i>Transplant Immunology</i> , 2021, 68, 101443.	0.6	0
84	Infection Ń SARS-CoV-2 et transplantation d'organes solides. <i>Revue Medicale Suisse</i> , 2020, 16, 815-818.	0.0	0